EZH2 and cancer: In addition to the association of GOF mutations in EZH2 with oncogenesis, some studies have implicated the overexpression of this gene in cancer development despite an absence of mutations in the coding region, such as in multiple myeloma [37,38,39], prostate, breast, and endometrial cancers [31,40].